SGC Frankfurt

 

The Structural Genomics Consortium at the Goethe University Frankfurt (SGC Frankfurt) is focused on the development of selective inhibitors (chemical probes), which help us to better understand the biological role of key signaling molecules and may serve as a starting point to target these proteins in different diseases. The SGC Frankfurt is committed to sharing its research in the spirit of Open Science.

 

 

News

 

December 2018

LRRK2 is a major target for Parkinson's disease therapies. Determination of a high-resolution crystal structure of the full-length LRRK2 protein or individual functional domains protein would help understanding the molecular basis of this disease and, importantly, provide a structural basis for rational drug design. Read more

 

November 2018

List of Highly Cited Researchers released. CSO of the SGC Frankfurt Stefan Knapp is one of the worlds’ most influential scientists as revealed by Clarivate Analytics’ Highly Cited Researchers List. Read more

 

Publications

 

Stolz A, Dikic I. Elusive mitochondrial connection to inflammation uncovered. Nature. 2018 Link

 

Drewes G, Knapp S. Chemoproteomics and Chemical Probes for Target Discovery. Trends Biotechnol. 2018 Link

 

Georgi V, Schiele F, Berger BT, Steffen A, Marin Zapata PA, Briem H, Menz S, Preusse C, Vasta JD, Robers MB, Brands M, Knapp S, Fernández-Montalván A. Binding Kinetics Survey of the Drugged Kinome. J Am Chem Soc. 2018 Link

Contact

 

Susanne Müller-Knapp
Chief Operating Officer
Tel: +49 (0) 69 798-42501
E-mail:
contact (at) sgc-frankfurt.de

Address:
Max-von-Laue-Straße 15,
60438 Frankfurt am Main